REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

31 May 2023 11:51

RNS Number : 1896B
Arix Bioscience Plc
31 May 2023
 

Arix Bioscience plc(the "Company")

PDMR notification & Director Shareholding

The Company today announces it has granted an executive award of nil cost options (the "Award") under the Arix Bioscience plc Executive Incentive Plan (the "Plan") to CEO Robert Lyne, which are subject to performance conditions over a three-year period from 1 January 2023 to 31 December 2025 (the "Performance Period"). The Award takes the form of an option to acquire up to 671,800 ordinary shares of £0.00001 each in the Company. Vested Shares are subject to a further two-year holding period, as set out in the Plan. The performance conditions attached to the Award are set out in the Director's Remuneration Report on page 55 of Company's Annual Report & Accounts 2022.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert Lyne

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP")

 c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

 

 

671,800

d)

 

Aggregated information

- Aggregated volume

N/A (Single Transaction)

- Price

N/A (Single Transaction)

e)

 

Date of the transaction

 

30 May 2023

f)

 

Place of the transaction

 

Outside a trading venue

For further information please contact:Kin Company Secretarial Limited, Company Secretary +44 20 8819 6486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBFLFXXELEBBB
Date   Source Headline
22nd Jun 20224:45 pmEQSHolding(s) in Company
22nd Jun 20227:00 amEQSNotice of Investor Presentation
22nd Jun 20227:00 amEQSNotice of Investor Presentation
9th Jun 20227:00 amEQSUnaudited NAV for May 2022
9th Jun 20227:00 amEQSUnaudited NAV for May 2022
7th Jun 20224:45 pmEQSResult of Annual General Meeting 2022
12th May 20229:00 amRNSCommunications with Shareholders
12th May 20227:00 amRNSPublication of Annual Report & Notice of AGM
11th May 20227:01 amEQSUnaudited NAV for April
9th May 20223:29 pmEQSClinical Development Update from Portfolio Company LogicBio
5th May 20227:01 amEQSFinancial Results for the Year Ended 31 December 2021
4th May 20226:39 pmRNSStatement Regarding Arix Bioscience plc
4th May 20227:01 amEQSTR-1: Notification of major holdings
29th Apr 202210:45 amEQSUnaudited NAV and Notice of Financial Results
5th Apr 20224:29 pmEQSImara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
14th Mar 202211:32 amEQSCorporate update from portfolio company Harpoon Therapeutics
25th Feb 20225:30 pmRNSClosed Period Notification
24th Feb 20228:00 amRNSCompany Secretary Change
8th Feb 20227:20 amEQSTotal Voting Rights
2nd Feb 20221:06 pmEQSArix Bioscience PLC: Clinical development update from portfolio company LogicBio
22nd Dec 202111:05 amEQSArix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
17th Dec 202111:13 amEQSArix Bioscience PLC: Director/PDMR Shareholdings
17th Dec 20217:00 amRNSDirector/PDMR Shareholding
15th Dec 20218:14 amEQSArix Bioscience PLC: Depixus raises €30.6M (£26.1 million) in Series A Financing
13th Dec 20213:54 pmEQSArix Bioscience PLC: Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
13th Dec 20213:51 pmEQSArix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021
17th Nov 20215:04 pmEQSImara Announces Interim Analysis Data From Forte Phase 2b Clinical Trial Of Tovinontrine (Imr-687) In Transfusion-Dependent Subjects With Beta-Thalassemia
8th Nov 20215:34 pmEQSTransaction in own shares
8th Nov 20211:00 pmEQSArix Bioscience PLC: Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
8th Nov 20217:01 amEQSArix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference
1st Nov 20217:01 amEQSTotal Voting Rights
29th Oct 20217:00 amEQSAura Biosciences prices Nasdaq IPO
18th Oct 20214:48 pmEQSLogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
18th Oct 20217:00 amEQSBusiness Update and Cancellation of Share Buyback
15th Oct 20215:30 pmEQSTransaction in own shares
14th Oct 20215:30 pmEQSTransaction in own shares
13th Oct 20215:30 pmEQSTransaction in own shares
13th Oct 20215:28 pmEQSTR1: Notification of Major Shareholding
12th Oct 20215:30 pmEQSTransaction in own shares
12th Oct 20211:02 pmEQSAura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting
11th Oct 20215:30 pmEQSTransaction in own shares
8th Oct 20215:30 pmEQSTransaction in own shares
8th Oct 202110:11 amEQSPyxis Oncology prices Nasdaq IPO - Update
8th Oct 20217:00 amEQSPyxis Oncology prices Nasdaq IPO
7th Oct 20215:30 pmEQSTransaction in own shares
6th Oct 20215:30 pmEQSTransaction in own shares
6th Oct 20217:00 amEQSBoard Changes
5th Oct 20215:30 pmEQSTransaction in own shares
4th Oct 20215:30 pmEQSTransaction in own shares
1st Oct 20215:30 pmEQSTransaction in own shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.